No takes yet. Share an insight, caveat, or question.
Cost-effectiveness analysis reveals low-dose zidovudine improves survival at viable costs in asymptomatic HIV infection, indicating favorable economic value relative to standard medical care.
Schulman et al. (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: